Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation

Table 3 The multiple Cox regression equations of different antiviral agents on recurrence within 6 months post radiofrequency

Variable	Crude model		Model I		Model II
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
ETV	1		1		1
TDF	0.86 (0.37, 2.02)	0.729	0.78 (0.32, 1.91)	0.593	1.01 (0.41, 2.53)	0.976
TAF	0.67 (0.23, 1.96)	0.470	0.70 (0.24, 2.03)	0.506	0.82 (0.27, 2.49)	0.730

Crude model was adjusted for no variable. Model I was adjusted for glutamyl transferase (GGT). Model II was adjusted for GGT, alpha-fetoprotein, Barcelona Clinic Liver Cancer. ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide fumarate.